Ria Dave
Research Subjects
Ria Dave has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Adrian A Sanchez
Mallinckrodt Institute of Radiology, Washington University School of Medicine , St. Louis, MO
1 shared publication- Aimee S. James
Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, Missouri
1 shared publication Alex T. Ramsey
1 shared publication- Aren Mnatzakanian
University College Dublin School of Medicine, Dublin, Ireland
1 shared publication - Beryne Odeny
Washington University St Louis, USA
1 shared publication Debbie L Bennett
Mallinckrodt Institute of Radiology, Washington University School of Medicine , St. Louis, MO
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by Elsevier in Journal of the American College of Radiology
From mammogram to lung scan: Lessons learned toward an implementation roadmap for integrating breast and lung cancer screening
- 7 November 2026
- Published by Elsevier in Journal of the American College of Radiology
Open AccessFrom mammogram to lung scan: Lessons learned toward an implementation roadmap for integrating breast and lung cancer screening
- 17 September 2026
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 8 (5) , 569-580
The Lead Interpreting Physician's Essential Guide: Core Responsibilities of the Lead Interpreting Physician Under the Mammography Quality Standards Act and the American College of Radiology Accreditation Standards
The Mammography Quality Standards Act (MQSA), enacted by Congress in 1992, established nationwide requirements to ensure the safety, consistency, and diagnostic quality of mammography in the United States. Compliance encompasses equipment performance, personnel qualifications, quality assurance and quality control activities, reporting standards, patient notification, and facility certification. Although individual MQSA components are straightforward, the cumulative responsibilities, particularly for the Lead Interpreting Physician (LIP), can be complex. This article provides a comprehensive overview of the MQSA regulatory framework, including the roles of federal and state entities, accreditation bodies, and key personnel essential to maintaining a compliant mammography program. We outline qualification and ongoing training requirements for interpreting physicians, technologists, and medical physicists; describe expectations for annual U.S. Food and Drug Administration (FDA) inspections; and summarize required processes for patient and provider communication, record retention, equipment evaluation, and the facility’s annual outcomes audit. The article also reviews the FDA’s Enhancing Quality Using the Inspection Program (EQUIP) initiative, which emphasizes continuous clinical image quality improvement, and highlights common reasons for inspection deficiencies. Key considerations for teleradiology, including diagnostic display testing and documentation standards, are discussed, as are updates introduced by the 2023 FDA rule, including mandatory breast density notification. By synthesizing regulatory requirements and practical operational strategies, this article aims to support LIPs and multidisciplinary breast imaging teams in developing efficient, sustainable systems that ensure high-quality mammographic care and ongoing MQSA compliance.
- 17 September 2026
- Published by Oxford University Press (OUP) in Journal of Breast Imaging
- Vol. 8 (5) , 569-580
The Lead Interpreting Physician's Essential Guide: Core Responsibilities of the Lead Interpreting Physician Under the Mammography Quality Standards Act and the American College of Radiology Accreditation Standards
The Mammography Quality Standards Act (MQSA), enacted by Congress in 1992, established nationwide requirements to ensure the safety, consistency, and diagnostic quality of mammography in the United States. Compliance encompasses equipment performance, personnel qualifications, quality assurance and quality control activities, reporting standards, patient notification, and facility certification. Although individual MQSA components are straightforward, the cumulative responsibilities, particularly for the Lead Interpreting Physician (LIP), can be complex. This article provides a comprehensive overview of the MQSA regulatory framework, including the roles of federal and state entities, accreditation bodies, and key personnel essential to maintaining a compliant mammography program. We outline qualification and ongoing training requirements for interpreting physicians, technologists, and medical physicists; describe expectations for annual U.S. Food and Drug Administration (FDA) inspections; and summarize required processes for patient and provider communication, record retention, equipment evaluation, and the facility’s annual outcomes audit. The article also reviews the FDA’s Enhancing Quality Using the Inspection Program (EQUIP) initiative, which emphasizes continuous clinical image quality improvement, and highlights common reasons for inspection deficiencies. Key considerations for teleradiology, including diagnostic display testing and documentation standards, are discussed, as are updates introduced by the 2023 FDA rule, including mandatory breast density notification. By synthesizing regulatory requirements and practical operational strategies, this article aims to support LIPs and multidisciplinary breast imaging teams in developing efficient, sustainable systems that ensure high-quality mammographic care and ongoing MQSA compliance.